See more : Perfect Medical Health Management Limited (1830.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Edesa Biotech, Inc. (EDSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edesa Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Ulima Nitra Tbk (UNIQ.JK) Income Statement Analysis – Financial Results
- Endeavour Mining plc (EDV.L) Income Statement Analysis – Financial Results
- KMA Holding, Inc. (MCDA) Income Statement Analysis – Financial Results
- CVS Health Corporation (CVS.DE) Income Statement Analysis – Financial Results
- ASMPT Limited (ASMVY) Income Statement Analysis – Financial Results
Edesa Biotech, Inc. (EDSA)
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 328.80K | 410.87K | 211.85K | 228.29K | 1.27M | 758.69K | 372.13K | 545.47K | 286.05K | 697.19K | 854.84K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 183.47K | 118.19K | 118.79K | 17.60K | 101.29K | 445.32K | 534.45K | 1.13M | 840.25K | 760.26K | 576.53K | 436.40K | 1.01M | 386.09K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -183.47K | -118.19K | -118.79K | 311.20K | 309.58K | -233.47K | -306.17K | 143.86K | -81.56K | -388.13K | -31.06K | -150.35K | -311.90K | 468.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 94.65% | 75.35% | -110.21% | -134.11% | 11.31% | -10.75% | -104.30% | -5.69% | -52.56% | -44.74% | 54.83% | 0.00% | 0.00% |
| Research & Development | 2.88M | 4.79M | 13.34M | 17.95M | 3.33M | 1.10M | 2.09M | 1.97M | 1.73M | 1.03M | 2.46M | 1.45M | 1.83M | 906.52K | 352.78K | 0.00 | 0.00 |
| General & Administrative | 4.13M | 4.43M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
| Selling & Marketing | 0.00 | -183.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.13M | 4.24M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
| Other Expenses | 0.00 | 0.00 | -780.26K | -10.34M | 37.41K | 0.00 | 0.00 | 0.00 | 24.63K | 0.00 | 0.00 | 0.00 | 112.14K | 87.33K | 30.37K | 0.00 | 0.00 |
| Operating Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.71M | 3.14M | 4.84M | 4.92M | 5.05M | 4.26M | 5.33M | 3.65M | 6.37M | 6.83M | 1.53M | 78.50K | 0.00 |
| Cost & Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.73M | 3.24M | 5.29M | 5.45M | 6.18M | 5.10M | 6.09M | 4.22M | 6.81M | 7.84M | 1.92M | 78.50K | 0.00 |
| Interest Income | 153.50K | 289.85K | 63.52 | 11.17K | 37.78K | 56.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.99K | 4.88K | 11.30K | 2.80K | 4.64K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73K | 58.00 | 0.00 |
| Depreciation & Amortization | 186.05K | 183.47K | 118.19K | 118.79K | 57.56K | 6.37K | 188.37K | 179.32K | 149.57K | 159.52K | 158.31K | 124.83K | 112.14K | 87.33K | 13.27K | 4.70K | 0.00 |
| EBITDA | -6.13M | -8.19M | -17.43M | -13.22M | -6.35M | -2.83M | -4.85M | -4.85M | -4.87M | -2.65M | -8.25M | -3.72M | -6.43M | -3.51M | -761.82K | -64.65K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -687.79% | -2,327.12% | -2,295.32% | -363.58% | -752.80% | -770.26% | 1,404.04% | -2,703.14% | -1,010.13% | -122.75% | 0.00% | 0.00% |
| Operating Income | -7.01M | -9.22M | -18.37M | -23.68M | -6.40M | -2.83M | -5.08M | -5.22M | -4.91M | -4.34M | -5.72M | -3.68M | -6.52M | -7.10M | -1.07M | -78.56K | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -689.30% | -2,397.11% | -2,288.59% | -385.97% | -571.85% | -1,536.69% | -674.37% | -2,280.23% | -1,018.37% | -124.63% | 0.00% | 0.00% |
| Total Other Income/Expenses | 845.50K | 849.14K | 822.67K | 10.34M | 37.41K | -309.45K | 40.10K | 194.70K | -110.52K | 1.53M | -2.78M | -11.21M | 1.37M | 3.50M | 477.02K | 4.64K | 0.00 |
| Income Before Tax | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.78M | -5.04M | -5.03M | -5.02M | -2.81M | -8.41M | -14.89M | -5.20M | -7.09M | -588.37K | -73.92K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.34% | -675.82% | -2,378.18% | -2,203.30% | -394.66% | -369.88% | -2,260.58% | -2,728.98% | -1,816.40% | -1,016.27% | -68.83% | 0.00% | 0.00% |
| Income Tax Expense | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | -55.40K | 800.00 | 800.00 | 7.20K | 36.80K | 27.20K | 800.00 | 800.00 | 800.00 | 1.60K | 0.00 | 0.00 |
| Net Income | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.72M | -5.04M | -5.03M | -5.03M | -2.84M | -8.44M | -14.89M | -5.20M | -7.09M | -589.97K | -73.92K | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.59% | -662.33% | -2,378.56% | -2,203.65% | -395.23% | -374.73% | -2,267.88% | -2,729.12% | -1,816.68% | -1,016.39% | -69.02% | 0.00% | 0.00% |
| EPS | -1.93 | -2.93 | -8.37 | -7.74 | -5.18 | -4.15 | -10.54 | -218.72 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
| EPS Diluted | -1.93 | -2.93 | -8.37 | -7.73 | -5.18 | -4.15 | -10.54 | -211.28 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
| Weighted Avg Shares Out | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.00K | 478.23K | 23.00K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
| Weighted Avg Shares Out (Dil) | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.32K | 478.23K | 23.81K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter TORONTO, ON / ACCESSWIRE / August 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA),...
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2021 and provided an...
Edesa Biotech Extends Dermatitis Study to Canada
TORONTO, ON / ACCESSWIRE / July 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has expanded patient enrollment to Canada for the final part of a...
EDSA Stock Price Increases Over 14% Pre-Market: Why It Happened
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 14% pre-market. This is why it happened.
Edesa Biotech Reports Favorable Review of COVID-19 Study
TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an independent Data and Safety Monitoring Board (DSMB) has completed an interim review of...
Edesa Biotech to Attend BIO Digital 2021
TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company's senior management are scheduled to attend the 2021 BIO Digital Conference being...
Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial
Edesa Biotech Inc's (NASDAQ: EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy for moderate to severe chronic Allergic Contact Dermatitis (ACD). Though blinded to treatment assignment, the study's Data and Safety Monitoring...
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's drug candidate EB01 has met a key interim study parameter. The company...
Edesa Biotech to Join Panel Discussion at Industry Event
TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by the Ontario Bioscience Innovation...
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2021 and provided an...
Source: https://incomestatements.info
Category: Stock Reports